Equities research analysts expect that Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) will post earnings of ($0.18) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Corbus Pharmaceuticals Holdings’ earnings. Corbus Pharmaceuticals Holdings also posted earnings per share of ($0.18) in the same quarter last year. The business is expected to announce its next earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Corbus Pharmaceuticals Holdings will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.59). For the next year, analysts anticipate that the business will post earnings of ($0.65) per share, with EPS estimates ranging from ($0.69) to ($0.61). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Corbus Pharmaceuticals Holdings.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%.

CRBP has been the topic of several recent research reports. ValuEngine downgraded shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. BidaskClub downgraded shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, September 20th. Finally, Noble Financial reaffirmed a “buy” rating and issued a $16.00 price target on shares of Corbus Pharmaceuticals Holdings in a report on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.75.

In other Corbus Pharmaceuticals Holdings news, Director David P. Hochman purchased 5,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction on Monday, November 13th. The shares were bought at an average price of $6.90 per share, with a total value of $34,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Hochman purchased 10,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the acquisition, the director now directly owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Insiders acquired 20,336 shares of company stock worth $142,882 in the last ninety days. Insiders own 11.90% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in CRBP. Bank of New York Mellon Corp lifted its stake in shares of Corbus Pharmaceuticals Holdings by 7.7% during the first quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,511 shares during the period. Vanguard Group Inc. lifted its stake in shares of Corbus Pharmaceuticals Holdings by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after buying an additional 71,419 shares during the period. Geode Capital Management LLC lifted its stake in shares of Corbus Pharmaceuticals Holdings by 16.5% during the first quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock valued at $1,659,000 after buying an additional 28,492 shares during the period. Credit Suisse AG purchased a new position in shares of Corbus Pharmaceuticals Holdings during the first quarter valued at approximately $157,000. Finally, Creative Planning lifted its stake in shares of Corbus Pharmaceuticals Holdings by 3.9% during the second quarter. Creative Planning now owns 173,475 shares of the biopharmaceutical company’s stock valued at $1,093,000 after buying an additional 6,525 shares during the period. 29.20% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Zacks: Analysts Anticipate Corbus Pharmaceuticals Holdings, Inc. (CRBP) to Post -$0.18 Earnings Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/16/zacks-analysts-anticipate-corbus-pharmaceuticals-holdings-inc-crbp-to-post-0-18-earnings-per-share.html.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at $6.60 on Thursday. Corbus Pharmaceuticals Holdings has a fifty-two week low of $5.30 and a fifty-two week high of $10.50.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Get a free copy of the Zacks research report on Corbus Pharmaceuticals Holdings (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.